Brachytherapy News and Research

RSS

Brachytherapy is a minimally invasive procedure that involves the use of radioactive seeds the size of rice grains. Brachytherapy, an out-patient procedure, usually takes 45 minutes to an hour to perform. Most patients can return to their normal activities within days. The success rates of prostate brachytherapy have compared favorably with success rates of radical prostatectomy and external beam radiation. In comparison studies, prostate brachytherapy has shown to have a favorable side effect profile when compared with other modalities. Clinical studies have shown that prostate brachytherapy has a cure rate of 94% for appropriately selected patients.

NeuroBlate Thermal Therapy System safe for treating recurrent glioblastoma, study shows

The first-in-human study of the NeuroBlate Thermal Therapy System finds that it appears to provide a new, safe and minimally invasive procedure for treating recurrent glioblastoma, a malignant type of brain tumor.

6 Apr 2013

Cancer patients to get benefit from Elekta's Versa HD system at Hôpital Riviera's radiotherapy clinic

Cancer patients referred to Hôpital Riviera's (Vevey, Switzerland) new radiotherapy clinic will soon benefit from the center's acquisition of Elekta's advanced new linear accelerator, Versa HD.

From Elekta 27 Mar 2013

Elekta launches Versa HD system to treat cancers

During a live global event, Elekta announced the launch of Versa HD, an advanced linear accelerator system designed to improve patient care and treat a broader spectrum of cancers.

From Elekta 2 Mar 2013

iCAD fourth quarter total revenue increases 18% to $7.8 million

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and twelve months ended December 31, 2012.

19 Feb 2013

Combination RT offers hope to late-stage esophageal cancer patients

Just over half of patients with advanced-stage esophageal cancer who are unsuitable for standard curative treatment survive for a year after receiving a combination of external beam radiotherapy and high-dose rate brachytherapy, report researchers.

7 Feb 2013

IsoRay announces presentation video on metastatic brain cancers by Cornell Weill

IsoRay Inc., a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the presentation video by Cornell Weill demonstrating their techniques in the successful treatment of metastatic brain cancers using IsoRay's patented Cesium-131 (Cs-131) sutured seeds.

6 Feb 2013

Delayed hematuria common after prostate brachytherapy

A significant proportion of patients with prostate cancer who are treated with brachytherapy develop gross hematuria years later, report researchers.

4 Feb 2013

RaySearch Laboratories receives order for RayStation treatment planning from Spain

RaySearch Laboratories AB has received an order for its RayStation® treatment planning from Consorcio Hospitalario Provincial de Castellón in Castellón, Spain.

25 Jan 2013

Surgical methods outperform radiation therapy in prostate cancer

A surgical method for treating localized prostate cancer may be a better option for patients than radiation therapy, show findings from a cost-effectiveness analysis.

9 Jan 2013

New study compares costs and outcomes associated with prostate cancer treatments

The most comprehensive retrospective study ever conducted comparing how the major types of prostate cancer treatments stack up to each other in terms of saving lives and cost effectiveness is reported this week by a team of researchers at the University of California, San Francisco.

7 Jan 2013

Perceived reduction in penis size linked to regrets of prostate cancer treatment choice

A small percentage of men in a prostate cancer study complained that their penis seemed shorter following treatment, with some saying that it interfered with intimate relationships and caused them to regret the type of treatment they chose.

3 Jan 2013

Elekta receives clearance for Clarity 4D Monitoring software

Elekta has received 510(k) clearance for its Clarity 4D Monitoring software, enabling U.S. medical centers to implement this new way of reducing the uncertainty caused by prostate motion during radiation treatment.

From Elekta 17 Dec 2012

Varian's TrueBeam receives Indian AERB clearance for use in advanced radiosurgical treatments

Varian Medical Systems has received regulatory clearance from the Indian Atomic Energy Regulatory Board for the use of its unique TrueBeam High Intensity Mode for advanced radiosurgical treatments.

29 Nov 2012

EMUC discusses current and future prospects in imaging for prostate cancer

At the 4th European Multidisciplinary Meeting on Urological Cancers (EMUC) held this weekend in Barcelona, Spain, specialists from radiology, urology, medical oncology and pathology said that new developments and research are already underway but benefits to patients would take some time due to the need for clinical trials, the high cost of funding research and the ability of cancer experts to efficiently take advantage of new insights and approaches, among other challenges.

19 Nov 2012

Promising new minimally toxic approach to treat solid tumors with radiation

A promising new approach to treating solid tumors with radiation was highly efficacious and minimally toxic to healthy tissue in a mouse model of cancer, according to data published in Cancer Research, a journal of the American Association for Cancer Research.

15 Nov 2012

Varian highlights numerous lung cancer treatment systems at ASTRO meeting

Varian Medical Systems highlighted the company's technologies for the non-invasive treatment of lung cancer at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston this week.

1 Nov 2012

Post-radiation drop in testosterone linked to recurrence of prostate cancer in men

Men whose testosterone drops following radiation therapy for prostate cancer are more likely to experience a change in PSA levels that signals their cancer has returned, according to new research from Fox Chase Cancer Center.

29 Oct 2012

Elekta Synergy system with Agility 160-leaf MLC now available at Radboud

The first of three newly acquired Elekta Synergy treatment systems equipped with Agility 160-leaf multi-leaf collimator (MLC) is now up and running clinically at Radboud University Nijmegen Medical Center - making the clinic the first in the Netherlands to use Agility.

From Elekta 15 Oct 2012

Theragenics enters second amended and restated credit agreement with Wells Fargo

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has entered into a Second Amended and Restated Credit Agreement with Wells Fargo Bank, National Association.

11 Oct 2012

Genetic profile predicts postradiation erectile dysfunction

Scientists have identified a group of genetic markers that can predict the risk for erectile dysfunction after radiotherapy for prostate cancer.

1 Oct 2012